Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Jonathan Andrew Nowak

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0943-7407; OpenAlex author ID A5058614093. Sources: OpenAlex.

Their work

Papers
41 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
176
Papers, trials and grants by year

2017: 1 paper · 2018: 4 papers · 2019: 4 papers · 2020: 3 papers · 2021: 5 papers · 2022: 2 papers · 2023: 6 papers · 2024: 7 papers · 2025: 1 paper · 2026: 8 papers

Papers 41

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  3. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  4. GLIS3 marks a neural-like progenitor cell state that drives metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2026.117314↗
  5. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Co-author DOI 10.1038/s43018-026-01165-8↗
  6. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  7. Pancreatic cancer-associated organ dysfunction promotes muscle autophagy and contributes to peripheral tissue wasting Co-author DOI 10.64898/2026.02.27.708635↗
  8. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  9. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  10. Big insights from small samples: uncovering the potential of EUS-guided FNAs in pancreatic cancer through predictive genomics and transcriptomics. Last author DOI 10.1016/j.ebiom.2024.105380↗
  11. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  12. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-1444↗
  13. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  14. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  15. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0873↗
  16. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  17. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Co-author DOI 10.1038/s41467-023-38088-2↗
  18. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  19. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  20. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  21. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  22. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Co-author DOI 10.14309/ctg.0000000000000573↗
  23. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-22-1125↗
  24. NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins. Co-author DOI 10.1158/2159-8290.cd-22-0043↗
  25. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.11.017↗
  26. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  27. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  28. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  29. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  30. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  31. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  32. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1055-9965.epi-19-1315↗
  33. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  34. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  35. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗
  36. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  37. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  38. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  39. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  40. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. First author DOI 10.1158/2159-8290.cd-18-0275↗
  41. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗

Closest collaborators

The 25 strongest of 176 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 37 shared papers, 2017–2026 · strength 4.62
  2. Andrew J. Aguirre · 20 shared papers, 2018–2026 · strength 2.56
  3. Douglas Adam Rubinson · 21 shared papers, 2017–2026 · strength 2.31
  4. Kimberly J. Perez · 17 shared papers, 2019–2026 · strength 2.30
  5. Chen Yuan · 20 shared papers, 2017–2026 · strength 2.04
  6. Kimmie Ng · 18 shared papers, 2017–2026 · strength 1.93
  7. Andressa Dias Costa · 16 shared papers, 2019–2026 · strength 1.93
  8. James M. Cleary · 13 shared papers, 2021–2026 · strength 1.92
  9. Harshabad Singh · 12 shared papers, 2021–2026 · strength 1.84
  10. Thomas E. Clancy · 14 shared papers, 2017–2026 · strength 1.51
  11. Brandon M. Huffman · 8 shared papers, 2021–2026 · strength 1.32
  12. Ana Babić · 14 shared papers, 2017–2024 · strength 1.25
  13. Stephanie K. Dougan · 8 shared papers, 2021–2026 · strength 1.20
  14. Srivatsan Raghavan · 8 shared papers, 2021–2026 · strength 1.12
  15. Joseph Douglas Mancias · 7 shared papers, 2022–2026 · strength 1.04
  16. Charles S. Fuchs · 13 shared papers, 2017–2023 · strength 0.98
  17. Vicente Morales‐Oyarvide · 12 shared papers, 2017–2023 · strength 0.92
  18. Matthew B.B. Yurgelun · 7 shared papers, 2019–2026 · strength 0.87
  19. Qiao-Li Wang · 5 shared papers, 2023–2026 · strength 0.76
  20. Rishi Surana · 5 shared papers, 2023–2026 · strength 0.74
  21. Sara A. Väyrynen · 8 shared papers, 2019–2023 · strength 0.71
  22. Michael Hayden Rosenthal · 5 shared papers, 2020–2026 · strength 0.70
  23. Hannah L. Williams · 6 shared papers, 2021–2025 · strength 0.70
  24. Albert C. Koong · 9 shared papers, 2017–2023 · strength 0.69
  25. Richard Francis Dunne · 9 shared papers, 2017–2023 · strength 0.69

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.